S211: Are Lower Urinary Tract Symptoms (LUTS) influenced by Metabolic Syndrome (MS)?

S211: Are Lower Urinary Tract Symptoms (LUTS) influenced by Metabolic Syndrome (MS)?

S211: Are Lower Urinary Tract Symptoms (LUTS) influenced by Metabolic Syndrome (MS)? Argirovic D.1, Argirovic A.2, Babic U.3, Antic A.2, Cvetkovic B.2...

62KB Sizes 4 Downloads 25 Views

S211: Are Lower Urinary Tract Symptoms (LUTS) influenced by Metabolic Syndrome (MS)? Argirovic D.1, Argirovic A.2, Babic U.3, Antic A.2, Cvetkovic B.2, Grebenarovic D.2 1

Clinic of Urology, Ccs, Outpatient Clinic Argirovic,, Dept. of Urology, Belgrade, Serbia, 2CHC Zemun, Belgrade, Dept. of Urology, Belgrade, Serbia, 3Clinic of Urology, CCS, Dept. of Urology, Belgrade, Serbia INTRODUCTION & OBJECTIVES: Middle-aged men often have LUTS resulting from benign prostatic hyperpasia (BPH). The correlation between MS and BPH remain debatable. The aim of the present study is to investigate the impact of MS on LUTS in middle-aged men receiving a healthy checkup. MATERIAL & METHODS: Males aged > 45 years who voluntary underwent the medical checkup were enrolled in this study. All participants were stratified into 2 groups by the presence of 3 or more risk factors including elevated body mass index (BMI), waist circumference (WC), fasting serum glucose and HbA1C, blood pressure, serum triglyceride, total and high density lipoprotein cholesterol. Prostate volume (PV) and prostate-specific antigen (PSA) level were used for subgroups analysis. RESULTS: Between January 2010 and December 2012, 354 men with men age 55.6±9.72 years, were enrolled into the study. According to reported criteria of MS, 108 (30.5%) had MS and formed the study group, whereas 246 (69.5%) MS-negative men formed a control group. Anthropometries including BMI and WC, as well as metabolic outcomes and percentage of hypertension were higher in MS vs. non-MS group (p<0.0001). The MS-group had a lower International Prostate Symptom Score (IPSS) (7.83±6.63 vs. 6.85±6.52) (p=0.05), lower severity of weak stream (1.24±1.60 vs. 0.95+7-1.50) (p=0.021) and lower severity of IPSS grading (p=0.014). In the larger PV (> 30 mL) and higher PSA (>0.93 ng/mL), total IPSS, storage and voiding score, urgency and incomplete emptying were lower in the MS group (p<0.05). However, in the small PV group, the MS and non-MS group were comparable on all factors. The negative association between voiding score, storage score, severity of LUTS and MS became particularly pronounced as the number of MS factors increased (p for trend < 0.001). However, the incomplete urinary emptying score was again lower in MS men with 5 MS risk factors in comparison with men without MS. Compared to the non-MS group, the odds ratio (OR) for moderate to severe LUTS was significantly lower in men with 3 (OR 0.61; 95% confidence interval [CI] 0.40-0.94) or 5 (OR 0.32; 95% CI 0.11-0.95) MS risk factors. Finally, men in the MS group were less likely to experience moderate to severe LUTS (OR 0.58; 95% CI 0.41-0.83).

CONCLUSIONS: We confirmed that MS had favorable effects on LUTS, including voiding and storage symptoms in healthy middle-aged men. This beneficial effect was most significant in men with enlarged prostate and/or high PSA level. Eur Urol Suppl 2014; 13(7) e1542